The role of several biomarkers in the early prediction or risk assessment of AKI has been proposed, including kidney tubular damage markers (e.g., neutrophil gelatinase-associated lipocalin (NGAL), kidney injury molecule-1 (KIM-1), liver-type fatty acid-binding protein (L-FABP)) [5–9], inflammation markers (e.g., interleukin-18 (IL-18)) [6, 10, 11], and stress markers (e.g., tissue inhibitor of metalloproteinases-2 and insulin-like growth factor-binding protein-7 (TIMP-2 ×  IGFBP-7)). This evidence concerns the gene LCN2 and acute kidney injury.